Characterization of olanzapine (LY170053) in human liver slices by liquid chromatography/tandem mass spectrometry

Journal of Mass Spectrometry

Volumn 33, Issue 12, 1998, Pages 1237-1245

  Murphy, A T ^a   Lake, B G ^b   Bernstein, J R ^a   Franklin, R B ^a   Gillespie, T A ^a  

^a ELI LILLY AND COMPANY   (United States)

^b BIBRA INTERNATIONAL   (United Kingdom)

Author keywords

Human; LC MS MS; Liver slice; Metabolism; Olanzapine

Indexed keywords

2 HYDROXYMETHYLOLANZAPINE; DRUG METABOLITE; LY 170055; LY 170238; LY 290411; LY 301664; N DESMETHYLOLANZAPINE; OLANZAPINE; OLANZAPINE GLUCURONIDE; OLANZAPINE LACTAM; UNCLASSIFIED DRUG;

ARTICLE; DRUG DETERMINATION; DRUG HYDROXYLATION; DRUG LIVER LEVEL; DRUG METABOLISM; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; LIVER SLICE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHILD; CHROMATOGRAPHY, LIQUID; GLUCURONATES; HUMANS; HYDROXYLATION; LIVER; MASS SPECTROMETRY; PIRENZEPINE;

EID: 0032438590     PISSN: 10765174     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9888(199812)33:12<1237::AID-JMS742>3.0.CO;2-F     Document Type: Article

References (22)

1. N. A. Moore, N. C. Tye, M. S. Axton and F. C. Risius, J. Pharmacol. Exper. Ther. 262, 545-551 (1992).
2. F. P. Bymaster, D. O. Calligaro, J. F. Falcone, R. D. Marsh, N. A. Moore, N. S. Tye, P. Seeman and D. T. Wong, Neuropsychopharmacol, 14, 87-96 (1996).
3. F. P. Bymaster, S. K. Hemrick-Luecke, K. W. Perry and R. W. Fuller, Psychopharmacol, 124, 87-94 (1996).
4. R. W. Fuller and H. D. Snoody, Pathology and Pharmacology, 77, 87-93 (1992).
5. C. M. Beasley, T. Sanger, W. Satterlee, G. Tollefson, P. Tran, S. Hamilton and Olanzapine HGAP Study Group, Psychopharmacol, 124, 159-167 (1996).
6. C. M. Beasley, G. Tollefson, P. Tran, W. Satterlee, T. Sanger, S. Hamilton and Olanzapine HGAP Study Group, Neuropsychopharmacol, 14, 105-118 (1996).
7. C. M. Beasley, S. Hamilton, A. M. Crawford, M. A. Dellva, G. Tollefson, P. Tran, O. Blin, J. N. Beuzen and Olanzapine E003 Study Group, European Neuropsychopharmacol, 7, 125-137 (1997).
8. G. Tollefson, C. M. Beasley, R. N. Tamura, P. Tran, J. H. Potvin, American Journal of Psychiatry, 154, 1248-1254 (1997).
9. P. Tran, M. A. Dellva, G. Tollefson, C. M. Beasley, J. H. Potvin, G. M. Kiesler, J. of Clin. Chem., 58, 205-211 (1997).
10. G. Tollefson and T. M. Sanger, American Journal of Psychiatry, 154, 466-474 (1997).
11. A. M. K. Crawford, C. M. Beasley and G. D. Tollefson, Schizophrenia Research, 26, 41-54 (1997).
12. K. Kassahun, E. L. Mattiuz, E. Nyhart, Jr., B. Obermeyer, T. A. Gillespie, A. T. Murphy, R. M. Goodwin, D. Tupper, J. T. Callahan and L. Lemberger, Drug Metab. Dispos., 25, 81-93 (1997).
13. A. E. Mutlib, Y. C. Chui, I. M. Young and F. S. Abbott, Drug Metab. Dispos., 21, 840-848 (1992).
14. S. R. Babu, V. M. Lakshmi, F. F. Hsu, R. E. Kane, T. V. Zenser and B. B. Davis, Carcinogenesis, 14(12), 2605-2611 (1993).
15. A. E. M. Vickers, S. Conners, M. Zollinger, W. A. Biggi, A. Larrauri, J. P. W. Volgellar, K. Brendel, Drug Met. Dispos., 21, 454-459 (1992).
16. T. A. Baillie, Inter. J. Mass Spectrom. and Ion Proc., 118/119, 289-314 (1992).
17. C. Fenselau and P. B. W. Smith, Xenobiotica, 22, 1207-1219 (1992).
18. G. K. Poon, Y. C. Chui, M. Jarman, M. G. Rowlands, P. S. Kokkonen, M. A. Niessen and J. Van der Greef, Drug Metab. Dispos., 20, 941-947 (1992).
19. S. W. Huskey, R. R. Miller and S. L. Chiu, Drug Metab. Dispos., 21, 792-799 (1993).
20. K. M. Schreiner, N. A. Farid, M. VandenBranden, S. A. Wrighton, ISSX Proceedings, 5th Annual North American Meeting, Tucson, AR., (1994).
21. Q. N. Porter and J. Baldas, Mass Spectrometry of Heterocyclic Compounds (New York: Wiley-Interscience, 1971).
22. M. W. Siaz and R. P. Remmel, Drug Metab. Dispos., 19, 149-153 (1990).